// App-Quantinova.ai

3310 : Post-Transplantation Cyclophosphamide Following Busulfan and Fludarabine Myeloablative Conditioning Prevents Severe Acute and Chronic Graft-Versus-Host Disease and Minimizes Duration Of Immunosuppression: Results Of a Multi-Institutional Trial In Patients With High-Risk Hematologic Malignancies

Researchers

Presenter

  • Christopher G. Kanakry

Principal Investigators

  • Paul V. -Donnell

  • Terry Furlong

  • Leo Luznik

  • Marcos J de Lima

  • Wei Wei

  • Marta Medeot

  • Marco Mielcarek

  • Richard E. Champlin

  • Richard J. Jones

  • Peter F. Thall

  • Borje S. Andersson

Medical Centers

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine,, Baltimore, MD

  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine,, Baltimore, MD

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Graft-versus-host disease

  • Hematological malignancies

  • Alpha-thalassemia myelodysplasia syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Busulfan

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved